Matricelf Ltd.
TTASE:MTLF245.50
ILA
-3.90
(-1.56%)
ISIN
IL0011767915
Return %
Stock
S&P 500
1Y
-40.70
14.20
3Y
-29.51
81.12
5Y
-82.72
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Semi-annual Revenue
FRC
•
in mil. unless spec.Semi-annual Earnings Per Share
FRC
•
in mil. unless spec.Semi-annual Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Asaf Toker
- Full Time Employees
- 15
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- Golda Meir 3 Ness Zion HM Israel 7651713
- IPO Date
- Jun 20, 2021
- Website
- matricelf.com
- Similar Companies
- Business
- Matricelf Ltd (TASE: MTLF) is an Israel-based preclinical-stage biotechnology company that develops a proprietary platform for autologous 3D tissue engineering and regenerative medicine using induced pluripotent stem cells (iPSCs) derived from patients' own blood cells combined with patient-specific extracellular matrix hydrogel from omentum tissue; the platform enables production of functional neural implants, tissues, and organs designed to restore function in damaged areas without triggering immune rejection. Core products and services focus on spinal cord injury treatments via engineered neural tissue bridges that demonstrate synchronized electrical activity and neural markers in preclinical models; the pipeline extends to stroke, traumatic brain injury, myocardial infarction, Parkinson's disease, age-related macular degeneration, and early research in cardiovascular and retinal diseases. Founded in 2019 as a spin-out from Tel Aviv University and headquartered in Ness Ziona, Israel, the company targets patients with severe neurological and degenerative conditions primarily in global markets, with operations centered in Israel and scalable manufacturing under development. Recent developments include a March 2025 global collaboration with Cellino to integrate Nebula AI-driven iPSC manufacturing for scalable spinal cord injury therapies, successful delivery of autologous iPSCs from four donors validating platform compatibility; an October 2025 agreement with Tel Aviv Sourasky Medical Center (Ichilov) for GMP clinical-grade neural tissue production ahead of planned 2026 first-in-human trials; and the appointment of Ron Mayron, former Teva Israel CEO, to the board with potential as chairman.